Press Releases

Forge and Evotec Present First Efficacy Data for LpxC Inhibitor in UTI Model at ASM Microbe 2017

San Diego, California, June 3, 2017 – Forge Therapeutics, Inc., (Forge), a biotechnology company discovering first-in-class antibiotics using a breakthrough drug discovery platform, ...

Forge and Evotec Present First Efficacy Data for LpxC Inhibitor in UTI Model at ASM Microbe 20172017-10-11T16:19:13-07:00

Forge Therapeutics to present new data on novel Gram-negative antibiotic program at ASM Microbe 2017

San Diego, California, May 24, 2017 – Forge Therapeutics, Inc., (Forge), a biotechnology company discovering first-in-class antibiotics using a breakthrough drug discovery platform, ...

Forge Therapeutics to present new data on novel Gram-negative antibiotic program at ASM Microbe 20172017-10-09T17:08:34-07:00

Forge Therapeutics attracts biotechnology leaders to join expanded board of directors

Board Composed of San Diego Biotech Veterans, Global Drug Development & Corporate Finance Leaders San Diego, California, May 16, 2017 – Forge Therapeutics, ...

Forge Therapeutics attracts biotechnology leaders to join expanded board of directors2017-10-09T22:02:22-07:00

Forge Therapeutics raises $15m Series A financing to develop first novel Gram-negative antibiotic in decades

Series A Complements Recent CARB-X Non-Dilutive Funding Forge Is Resourced And Financed Into The Clinic  San Diego, California, April 25, 2017 – Forge ...

Forge Therapeutics raises $15m Series A financing to develop first novel Gram-negative antibiotic in decades2017-10-11T16:20:04-07:00

Forge Therapeutics Wins Powered by CARB-X Research Award of $8.8M to Accelerate Development of its LpxC Antibiotic to Kill the World’s Deadliest ‘Superbugs’

San Diego, Calif., March 30, 2017 – Forge Therapeutics, Inc., (“Forge”), a biotechnology company discovering first-in-class antibiotics using a breakthrough drug discovery platform, ...

Forge Therapeutics Wins Powered by CARB-X Research Award of $8.8M to Accelerate Development of its LpxC Antibiotic to Kill the World’s Deadliest ‘Superbugs’2017-10-09T22:04:13-07:00

Forge Therapeutics to Present at Biocom Global Life Science Partnering Conference

Company to discuss novel antibiotic program targeting LpxC to kill Gram-negative superbugs  San Diego, Calif., February 28, 2017 – Forge Therapeutics, Inc., a ...

Forge Therapeutics to Present at Biocom Global Life Science Partnering Conference2017-10-09T17:16:04-07:00

Forge Therapeutics and Evotec Form Strategic ‘Superbug’ Alliance – Combination of leading innovative chemistry efforts with cutting edge anti-infective drug discovery platform –

San Diego, Calif., December 9, 2016 – Forge Therapeutics, Inc. today announced a strategic alliance with Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ...

Forge Therapeutics and Evotec Form Strategic ‘Superbug’ Alliance – Combination of leading innovative chemistry efforts with cutting edge anti-infective drug discovery platform –2017-10-10T16:05:19-07:00

Forge Therapeutics Adds Superbug Experts Drs Brad Spellberg and Andrew Tomaras to Leading Antibiotic Advisory Team

San Diego, Calif., September 12, 2016 – Forge Therapeutics, Inc. announced the additions of Dr. Brad Spellberg, M.D., Chief Medical Officer of Los ...

Forge Therapeutics Adds Superbug Experts Drs Brad Spellberg and Andrew Tomaras to Leading Antibiotic Advisory Team2017-10-09T22:06:55-07:00
Load More Posts
Go to Top